Skip to main content
Editas Medicine, Inc. logo

Editas Medicine, Inc. — Investor Relations & Filings

Ticker · EDIT ISIN · US28106W1036 LEI · 5299000AON4Q9NT2JE42 US Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2018-05-03 Earnings Release
Country US United States of America
Listing US EDIT

About Editas Medicine, Inc.

https://www.editasmedicine.com/

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2018, reporting the issuance of a press release announcing financial results for the fiscal quarter ended March 31, 2018. The text explicitly states that the press release is furnished as an exhibit and is not filed as part of the report. The document does not contain the actual financial results or detailed financial statements but rather announces the release of such information. The length of the document is 3467 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements of financial results press releases filed on Form 8-K are classified as Earnings Release (ER) since they provide initial announcement of quarterly financial results (key highlights only).
2018-05-03 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting for an annual meeting. It includes information about voting methods, meeting details, and recommendations from the Board of Directors on election of directors and ratification of auditors. It does not contain financial statements or detailed financial analysis, but rather materials to solicit shareholder votes. The document is titled 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and includes definitive additional materials for the proxy. This matches the definition of 'Remuneration Information' filings (DEF 14A), which cover executive compensation and proxy statements. Therefore, the correct classification is DEF 14A with high confidence.
2018-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-27 English
FORM 4 -
Director's Dealing
2018-04-04 English
FORM 4 -
Director's Dealing
2018-03-28 English
FORM 3 -
Director's Dealing
2018-03-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.